Investor Presentaiton
R&D investor presentation
CANTOS post-hoc analysis: MACE reduction only in patients
whose IL-6 was lowered below median
No. at risk:
Placebo
Canakinumab:
Cumulative Incidence
0.00
0.05
0.10
0.15
0.20
0.25
HR (95% CI)
Placebo
On Treatment IL-6: >=1.65 ng/L
1.0
1.06
(ref)
P
(ref)
(0.90.1.25) 0.49
On Treatment IL-6: <1.65 ng/L
0.64 (0.54,0.77) <0.0001
1
2
3
4
5
LO
Follow-up (years)
1597
1501
1411
1254
635
153
1619
1617
1524
1559
1211
562
123
1371
772
211
IL1B lowering
Limited IL6
effect
Significant IL6
effect
No CVD effect
IL-6 >=1.65 ng/L
IL-6 <1.65 ng/L
1411
1501
Source: Eur Heart J, Volume 39, Issue 38, 07 October 2018, Pages 3499-3507. MACE: Major adverse cardiovascular events; CVD: Cardiovascular disease; HR: Heart rate.
CVD risk
lowering
25View entire presentation